INBX News and Press, Inhibrx Inc. From 05/24/24

2024-05-24 15:00:53 ET More on the markets S&P 500: It Is All About Liquidity SPY: Time To Be Contrarian And Underweight SPY ETF: Momentum Is In The Cards Stocks have more room to run - Invesco's Kristina Hooper Big bear Mike Wilson changes tune a...

Inpixon (INPXV) is expected to report for Q1 2024 Siebert Financial Corp. (SIEB) is expected to report for Q1 2024 Greenwave Technology Solutions Inc. (GWAV) is expected to report for Q1 2024 Bank Hapoalim B.M. ADR (BKHYY) is expected to report for Q1 2024 Gelesis Holdings, Inc. (...

Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...

Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off PR Newswire SAN DIEGO , May 10, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") today announced that in connection with the previously announced dist...

Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger PR Newswire SAN DIEGO , May 8, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company"...

2024-04-16 12:22:50 ET More on rare disease pharmas/biotechs Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy Sarepta Therapeutics: Another 'Hold' Call Ahead Of Some Key Catalysts Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success...

2024-04-02 14:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-13 11:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results PR Newswire SAN DIEGO , Feb. 28, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with three clinical programs in development and a strong eme...

NEW YORK, NY / ACCESSWIRE / February 10, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Inhibrx, Inc. (NASDAQ: INBX)'s...